ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
End-stage renal disease due to atypical hemolytic–uremic syndrome developed in a woman at 25 years of age. At 30 years of age, after 5 years of undergoing dialysis, she received a cadaveric renal ...
CD59 may inhibit the cytolytic activity of complement by binding to C8/C9 and protect host cell membranes against homologous membrane attack complex (MAC). However, CD59 is widely overexpressed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results